SUBSCRIBE
SUBSCRIBE

Cassava Sciences Inc.

NEWS
Deals
Top 2003 Stories From The BioSpace NewsBeat
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
Lone Star Bio
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NYCEO to Present on Wednesday, October 11th, at 10:30am ET
October 5, 2023
 · 
1 min read
Drug Development
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
October 2, 2023
 · 
6 min read
Drug Development
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
September 18, 2023
 · 
5 min read
Lone Star Bio
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
September 11, 2023
 · 
8 min read
Lone Star Bio
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences - September 06, 2023
September 6, 2023
 · 
1 min read
Business
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
August 3, 2023
 · 
8 min read
Lone Star Bio
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
July 5, 2023
 · 
12 min read
Lone Star Bio
New Research Shows Simufilam Suppresses Overactive mTOR
June 27, 2023
 · 
5 min read
Lone Star Bio
New Publication Highlights Basic Science Supporting Simufilam
June 12, 2023
 · 
5 min read
Lone Star Bio
Cassava Sciences to Present at the 2023 Jefferies Global Healthcare Conference
June 1, 2023
 · 
2 min read
Load More